ABVC BioPharma, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0K | — | — | $50.0M | $0 | $7.8K | $5.7K | $3.2K |
| Cost of Revenue | $185.3K | — | $32 | $521 | $0 | — | — | — |
| Gross Profit | $-178.3K | — | $-32 | $2.8K | $0 | — | — | — |
| Gross Margin | -2,563.6% | — | — | 0.0% | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $988.7K | $3.2M | $10.0M | — | — | — | — | — |
| SG&A Expense | $1.6M | $811.7K | $599.3K | — | — | — | — | $1.9M |
| Operating Income | $-2.8M | $-4.1M | $-11.0M | — | — | $-177.3K | $-1.1M | $-1.9M |
| Operating Margin | -40,031.1% | — | — | — | — | -2,276.3% | -20,004.3% | -59,180.7% |
| Interest Expense | $462.8K | $103.5K | $10.2K | $0 | $0 | $49.1K | $87.7K | $204.9K |
| Pretax Income | $-6.4M | $-4.2M | $-11.0M | — | — | — | — | — |
| Income Tax Expense | $-365.1K | $830 | $836 | — | — | $0 | $67.6K | $0 |
| Net Income | $-6.1M | $-4.2M | $-11.0M | $-32.3K | $-23.2K | $-226.4K | $-1.1M | $-1.2M |
| Net Margin | -87,184.2% | — | — | -0.1% | — | -2,906.8% | -18,718.6% | -38,202.2% |
| EPS (Basic) | $-0.01 | $-0.01 | $-0.02 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS (Diluted) | $-0.01 | $-0.01 | $-0.02 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 641.7M | 640.0M | 581.9M | 585.1M | 585.4M | 2.87T | 743.79B | 511.58B |
| Shares Outstanding (Diluted) | 641.7M | 640.0M | 581.9M | 585.1M | 585.4M | 2.87T | 743.79B | 511.58B |
| Dividends Per Share | — | — | — | — | — | — | — | — |